With A Vitamin Type Active Ingredient Patents (Class 514/168)
-
Patent number: 6740676Abstract: Compounds of Formula 1: wherein the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.Type: GrantFiled: March 19, 2002Date of Patent: May 25, 2004Assignee: Allergan, Inc.Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok-Yin Tsang, Yang-Dar Yuan, Roshantha S. Chandraratna
-
Publication number: 20040086574Abstract: The present invention relates to compositions without added iron and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, alpha lipoic acid, and lutein, wherein the composition is free of added iron.Type: ApplicationFiled: October 14, 2003Publication date: May 6, 2004Inventors: John A. Giordano, Charles Balzer
-
Patent number: 6730308Abstract: The present invention relates to a method of treating psoriasis and/or photo damage in humans with tazarotene in a topical composition from 0.01 to 15% by weight tazarotene, and an alpha or beta-hydroxy acid in a topical composition comprising from 1 to 25% by weight alpha or beta-hydroxy acid. Furthermore, the present invention relates to treating or preventing psoriasis and/or photo damage by topically applying to the skin of a human, tazarotene, such as a gel comprising 0.01% to 0.1%, tazarotene by weight, and an alpha hydroxy acid, such as a cream, comprising 5% to 20% alpha hydroxy acid, e.g. glycolic acid, by weight.Type: GrantFiled: March 8, 1999Date of Patent: May 4, 2004Assignee: Allergan, Inc.Inventor: John Sefton
-
Publication number: 20040071753Abstract: The development and growth of oviparous species such as birds is enhanced by in ovo administration of an enteric modulator such as HMB. The enteric modulator is administered into the amnion, where it is then orally ingested by the subject. The enteric modulator enhances the enteric development of the subject prior to hatch, and enhances the growth of the animal before and after hatch.Type: ApplicationFiled: June 30, 2003Publication date: April 15, 2004Applicants: North Carolina State University, Yissum Research Development Company of the Hebrew University of JerusalemInventors: Zehava Uni, Peter R. Ferket
-
Publication number: 20040062821Abstract: Therapeutic anti-fatigue compositions for administration to a subject including an active combination of a compound of magnesium and sulfur such as magnesium thiosulfate and a mixture of vitamins including A, B6, B12 and D. The combination is present in the composition in an amount sufficient to treat the symptoms of fatigue in a subject. Methods of using such compositions for treating or managing fatigue are also encompassed by the invention.Type: ApplicationFiled: October 1, 2002Publication date: April 1, 2004Inventor: Elena Avram
-
Publication number: 20040058012Abstract: The present invention relates to a method of supplementing the dietary needs of women whereby an effective amount of a life stage appropriate dietary supplement is administered to a woman at each of her life stages throughout her life.Type: ApplicationFiled: September 11, 2003Publication date: March 25, 2004Inventors: Sherry D. Jackson, Jeffrey B. Blumberg
-
Publication number: 20040034098Abstract: Chronological aging of human skin can be delayed with the topical application of an MMP inhibitor, preferably a retinoid (an indirect MMP inhbitor); retinoids also normalize procollagen biosynthesis. Chronological aging, or natural aging, is evidenced in elderly (80+ years old) skin by increased MMP levels and decreased procollagen levels when compared with younger individuals. Prophylactic treatment of not yet chronologically-aged skin with a retinoid both inhibits degradation of dermal collagen and restores procollagen synthesis. Biopsied sections from elderly skin show that a single treatment of chronologically-aged skin with a retinoid can increase epidermal thickness, improve the dermal collagen density, and promote the formation of rete pegs and dermal papillae. Such benefits are helpful in preventing bruising, tearing, and ulceration of elderly skin. Accordingly, prophylactic treatment begun much earlier in life with an MMP inhibitor and/or a retinoid delays the onset of such symptoms.Type: ApplicationFiled: June 10, 2003Publication date: February 19, 2004Inventors: James Varani, Gary J. Fisher, John J. Voorhees, Sewon Kang
-
Patent number: 6686340Abstract: The invention relates to a method of administering to a human subject a composition comprising a vitamin, an amino acid and a trace element for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body like high blood pressure, asthma, glaucoma and tinnitus. The composition comprises a vitamin such as ascorbic acid, an amino acid such as arginine, and a trace element such as magnesium.Type: GrantFiled: June 19, 2001Date of Patent: February 3, 2004Inventor: Matthias Rath
-
Publication number: 20040013743Abstract: The present invention relates to dietary supplements containing low doses of phytoestrogens for supplementing the specific phytochemical dietary needs of perimenopausal and menopausal women.Type: ApplicationFiled: June 23, 2003Publication date: January 22, 2004Inventor: Sherry D. Jackson
-
Patent number: 6680309Abstract: Methods for the utilization of hypocalcemic vitamin D analogs to inhibit the hyperproliferation of malignant or neoplastic cells without incidence of hypercalcemia.Type: GrantFiled: January 7, 2003Date of Patent: January 20, 2004Assignee: Bone Care International, Inc.Inventors: Charles W. Bishop, Richard B. Mazess
-
Publication number: 20040009235Abstract: The invention provides a hydroxyapatite composition for replenishing calcium, comprising 5 to 80 wt % hydroxyapatite with particle size of 5-800 nm and pharmaceutically acceptable excipient. The composition may comprise organic acid, such as citric acid, malic acid, starch, dextrin, sugar, Vitamin D, Vitamin A, Vitamin B, Vitamin C, and Vitamin E, and trace clement(s) selected from the group consisting of Sr, F, Fe, Zn, and Mn. The composition may be in solid preparation form such as powder, tablet, including coated tablet, capsule, and infusion (medicinal granules), and liquid preparation form such as oral liquid, injection solution, and beverage; and ion introduction type transdermal-preparation, etc. Furthermore the composition can be incorporated into any other foods. The composition of the invention can be made into different type of products including general type, children type, pregnant women type, liver and kidney type and climacteric type to meet the need of different people.Type: ApplicationFiled: June 12, 2003Publication date: January 15, 2004Inventor: Jinghong Li
-
Publication number: 20040005366Abstract: The key to the unique formulation is a combination of specific vitamins, minerals, herbs and nutrients. These essential components in the amounts provided uniquely contribute to improved blood sugar levels and insulin delivery to the cells. The formulation contains essential amounts of Calcium, magnesium Vitamin D, Vitamin K-1, Folic Acid and Soy Isoflavones, as well as other ingredients and healthy filler components.Type: ApplicationFiled: July 3, 2002Publication date: January 8, 2004Inventor: Wayne F. Gorsek
-
Publication number: 20040005305Abstract: A nutritional composition is described for prevention or treatment of an immune condition. The composition includes at least vitamin E, vitamin C, vitamin B6, folic acid, vitamin B12, copper, zinc, selenium, fructo-oligosaccharides and/or gum acacia, a probiotic lactic acid bacterium. For example, in an embodiment it comprises per 300 g: 150 IU Vitamin E, 120 mg Vitamin C, 2 mg Vitamin B6, 400 ug Folic acid, 3.8 ug Vitamin B12, 1.5 mg Copper, 15 mg Zinc, 100 ug Selenium, 3 g Fructo-oligosaccharides and/or gum acacia, 10E10 cfu ST11 lactobacillus. Also disclosed are a method for making the nutritional composition, a method for manufacturing a functional food or medicament; and a method of prevention or treatment of an immune condition by administering an effective amount of the composition, functional food or medicament.Type: ApplicationFiled: May 13, 2003Publication date: January 8, 2004Inventors: Evelyn Spivey-Krobath, Claude Cavadini, Ferdinand Haschke, Veronique Jaussan, Eduardo Schiffrin
-
Publication number: 20030229056Abstract: Composition for the aqueous stabilization of fat-soluble vitamins that comprises: (i) an alcohol with 4 to 8 carbon atoms (ii) 0.5 to 3 mass unit of amine or amide having 2 to 8 carbon atoms calculated for a unity mass of alcohol; and/or (iii) 1.5 to 6 mass unit of carboxylic acid with 8 to 18 carbon atoms calculated for a unity mass of alcohol. The composition is used in stabilized pharmaceutical or veterinary preparations having an aqueous medium.Type: ApplicationFiled: December 30, 2002Publication date: December 11, 2003Inventor: Andras Bertha
-
Publication number: 20030225044Abstract: A method to increase blood levels in animals, including humans, of one or more vitamins by administering those one or more vitamins to the animal's nasal pharynx, such that the blood levels of each of those one or more vitamins increases throughout about a 6 hour period post-dosing, and optionally, throughout a 24 hour period post-dosing. A method to increase blood levels in animals, including humans, of one or more vitamins by administering those one or more vitamins to the animal's buccal cavity, such that the blood levels of each of those one or more vitamins increases throughout about a 6 hour period post-dosing, and optionally, throughout a 24 hour period post-dosing.Type: ApplicationFiled: June 3, 2002Publication date: December 4, 2003Inventors: Stephen E. Bachman, Michael E. Hubbert
-
Publication number: 20030223953Abstract: A cosmetic composition is shown for rejuvenating the appearance of skin with reduced or minimal potential for skin irritation, in the form of a lotion or cream which includes as a major component aloe vera as well as vitamins A, B, C, D and E.Type: ApplicationFiled: February 6, 2003Publication date: December 4, 2003Inventor: Myong Hun Chong
-
Publication number: 20030216359Abstract: This invention relates to combination chemotherapy, particularly involving vitamin D or a derivative thereof. In one aspect, the invention provides a method of killing a cell by first administering to the cell vitamin D (or a derivative) and subsequently administering to the cell a cytotoxic agent. Where this strategy is applied to an intact tumor, the present invention provides a method of retarding the growth of the tumor by first administering vitamin D (or a derivative) to the tumor and subsequently administering the cytotoxic agent. A further aspect of the invention concerns a method of treating prostate cancer within a patient by co-administration of vitamin D (or a derivative) and a glucocorticoid to the patient. In yet a further aspect, the invention provides an improved method of treating a patient with vitamin-D involving the adjunctive administration of zoledronate.Type: ApplicationFiled: May 5, 2003Publication date: November 20, 2003Applicant: University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Candace S. Johnson, Donald L. Trump
-
Publication number: 20030207848Abstract: A composition is described comprising a vitamin D analog and a retinoid wherein: (a) the vitamin D analog is capable of binding a vitamin D receptor or being converted in vivo into a compound capable of binding a vitamin D receptor; and (b) the retinoid is selected from the group consisting of retinol in a concentration of at least about 1.0%, a compound in a concentration of at least about 1.0% capable of being converted in vivo into retinol, and a retinoid characterized by having a substitution at the 4-position. Further, methods of treating disorders characterized by abnormal cell-proliferation and/or cell-differentiation are also described.Type: ApplicationFiled: April 17, 2003Publication date: November 6, 2003Applicant: Gentrix LLCInventor: Charles C. Achkar
-
Publication number: 20030206963Abstract: A highly safe bone resorption suppressing agents, which can be used as medicines or admixed to food products or feeds, is produced. Milk-derived basic cystatins and/or milk-derived basic cystatin decomposition products prepared from milk are made into bone resorption suppressing agents, or admixed to drinks, food products and feeds.Type: ApplicationFiled: April 18, 2003Publication date: November 6, 2003Inventors: Yukihiro Takada, Atsushi Serizawa, Hidetoshi Ishikawa, Tomoe Yoshioka, Seiichiro Aoe
-
Publication number: 20030190369Abstract: The present invention provides a method and composition for dietary vitamin supplementation utilizing a form and dosage of vitamins and minerals for enhanced calcium absorption. The method includes the steps of providing a pharmaceutically acceptable composition including calcium citrate, and supplementing the daily dietary regimen of a subject with calcium citrate within the range of approximately 100 mg calcium to approximately 2000 mg calcium, and preferably 1000 mg calcium. The chewable form of the supplement provided herein facilitates absorption of calcium in the teeth and bones of a subject, for enhanced physiological and psychological benefits. The supplement is especially beneficial for subjects experiencing osteoporosis, arthritis, demineralization of teeth and bones, bodily pain and lack of energy, as well as for the prevention of these ailments.Type: ApplicationFiled: April 9, 2003Publication date: October 9, 2003Inventor: William E. Lovett
-
Patent number: 6624154Abstract: The invention relates to compositions comprising a retinoid X receptor agonist and an agent capable of activating protein kinase A. The invention also relates to methods of treating hyperproliferative diseases by administering a retinoid X receptor agonist and an agent capable of activating protein kinase A.Type: GrantFiled: April 21, 2000Date of Patent: September 23, 2003Assignees: Bristol-Myers Squibb Company, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Louis PasteurInventors: GĂ©rard Benoit, Hinrich Gronemeyer, Michel Lanotte, Marco Gottardis
-
Publication number: 20030176403Abstract: The invention provides a method of treating a patient with vitamin-D or a derivative thereof involving the adjunctive administration of zoledronate.Type: ApplicationFiled: March 17, 2003Publication date: September 18, 2003Applicant: University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Candace S. Johnson, Donald J. Trump
-
Publication number: 20030148992Abstract: A therapeutic formulation in the form of a beadlet, suitable for oral administration and adapted to provide immediate and sustained release of therapeutic material. Each beadlet comprises an extruded-spheronized inner core containing at least one medicament e.g. a slow release vitamin, an outer layer containing at least one medicament e.g. a fast release vitamin and a controlled release coating between the inner core and the outer layer which coating controls the release of the inner core medicament.Type: ApplicationFiled: January 16, 2003Publication date: August 7, 2003Inventors: Juergen Block, Stefan Heim, Ralf Westerheide
-
Patent number: 6602512Abstract: A composition is disclosed suitable for the prevention and/or treatment of muscular energetic deficiencies and states of asthenia for enhancing sport performances and for the treatment of states of heart fatigue, that may take the form of a dietary supplement, dietetic support or of an actual medicine, which comprises as characterizing active ingredients a combination of L-carnitine and/or at least one alkanoyl L-carnitine and creatinol-phosphate.Type: GrantFiled: January 3, 2002Date of Patent: August 5, 2003Assignee: Sigma-Tau HealthScience S.p.A.Inventor: Claudio Cavazza
-
Patent number: 6599513Abstract: The present invention provides novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in products for topical application to the skin. The products are very mild to the skin and may be easily formulated into a wide variety of personal care and dermatological products.Type: GrantFiled: October 24, 2001Date of Patent: July 29, 2003Assignee: Sembiosys Genetics Inc.Inventors: Harm M. Deckers, Gijs Van Rooijen, Joseph Boothe, Janis Goll, Maurice M. Moloney
-
Patent number: 6596708Abstract: A composition for the treatment and prevention of endothelial dysfunction comprising a therapeutically effective amount of anti-inflammatory agents comprising; acetylsalicylic acid, an amino sugar and a zinc compound.Type: GrantFiled: September 7, 2001Date of Patent: July 22, 2003Assignee: Advanced Medical InstrumentsInventor: Edward J. Petrus
-
Publication number: 20030125310Abstract: The present invention relates to stable emulsions and dry powders of mixtures of fat-soluble vitamins, and to processes for their preparation and to their use.Type: ApplicationFiled: November 18, 2002Publication date: July 3, 2003Inventors: Wolfgang Hahnlein, Morten Mohr Hansen, Jes Elenius Olesen, Anne Grethe Tobiasen
-
Patent number: 6582710Abstract: The present invention provides novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in products for topical application to the skin. The products are very mild to the skin and may be easily formulated into a wide variety of personal care and dermatological products.Type: GrantFiled: January 29, 2002Date of Patent: June 24, 2003Assignee: Sembiosys Genetics Inc.Inventors: Harm M. Deckers, Gijs van Rooijen, Joseph Boothe, Janis Goll, Maurice M. Moloney
-
Publication number: 20030103954Abstract: An oral composition for the prevention, reduction or treatment of radiation injury including one or more compounds that regulates cell differentiation and/or cell proliferation, and one or more antioxidants, optionally formulated in a pharmaceutically acceptable carrier for an oral composition. The composition of the present invention may further include optional ingredients such as flavonoids, flavonoid derivatives, selenium, selenium compounds, anti-inflammatories, organic germanium, Korean ginseng, American ginseng, Siberian ginseng and B-complex vitamins. A method for the administration of an oral composition for the purpose of preventing, reducing or treating radiation injury involves orally administering an effective amount of a composition including one or more compounds that regulates cell differentiation and/or cell proliferation, and one or more antioxidants to a person before, during or after radiation exposure.Type: ApplicationFiled: January 14, 2002Publication date: June 5, 2003Inventor: Richard A. Rosenbloom
-
Publication number: 20030105027Abstract: A nutritional supplement composition for the prevention, reduction or treatment of radiation injury due to exposure to ionizing radiation, including one or more compounds that regulates cell differentiation and/or cell proliferation, and one or more antioxidants, optionally formulated in a pharmaceutically acceptable carrier for an oral composition. The composition of the present invention may further include optional ingredients such as flavonoids, flavonoid derivatives, selenium, selenium compounds, anti-inflammatories, organic germanium, Korean ginseng, American ginseng, Siberian ginseng and B-complex vitamins. A method for the administration of an oral composition for the purpose of preventing, reducing or treating radiation injury involves orally administering an effective amount of a composition including one or more compounds that regulates cell differentiation and/or cell proliferation, and one or more antioxidants to a person before, during or after radiation exposure.Type: ApplicationFiled: April 25, 2002Publication date: June 5, 2003Inventor: Richard A. Rosenbloom
-
Publication number: 20030103953Abstract: A composition for the preventing, reducing or treating radiation dermatitis includes a mixture of one or more compounds that regulates cell differentiation and/or cell proliferation, and one or more antioxidants formulated in a pharmaceutically acceptable carrier. The composition of the present invention may further include a flavonoid. A method for the topical administration of the composition in accordance with the present invention for the purpose of preventing, reducing or treating radiation dermatitis involves topically administering an effective amount of the composition of the invention an area of skin which has been or will be exposed to radiation. The composition and method can be employed to prevent, reduce or treat radiation dermatitis caused by a wide variety of types of radiation exposure and is particularly useful for the prevention, reduction or treatment of radiation recall dermatitis.Type: ApplicationFiled: November 6, 2001Publication date: June 5, 2003Inventor: Richard Allen Rosenbloom
-
Patent number: 6573256Abstract: Methods utilizing active vitamin D analogs for the inhibition of angiogenesis associated with malignant and neoplasmic cells. Methods comprise the application of an effective amount of a hypocalcemic vitamin D compound to inhibit the angiogenesis of malignant cells, inducing the apoptosis of malignant cells, and regressing the growth of tumorous cells.Type: GrantFiled: June 26, 2001Date of Patent: June 3, 2003Assignee: Bone Care International, Inc.Inventors: Charles W. Bishop, Richard B. Mazess
-
Patent number: 6566353Abstract: Methods utilizing active vitamin D analogs for the treatment of malignancy-associated hypercalcemia. Methods comprise the application of an effective amount of a hypocalcemic vitamin D compound to alleviate hypercalcemia, lower serum parathyroid hormone related protein (PTHrP) levels.Type: GrantFiled: June 26, 2001Date of Patent: May 20, 2003Assignee: Bone Care International, Inc.Inventors: Charles W. Bishop, Richard B. Mazess
-
Patent number: 6565891Abstract: A multinutrient nutritional supplement is provided that is designed to be most effective in optimizing health, increasing the immunity and decreasing the instances and severity of infection particularly among children.Type: GrantFiled: August 23, 2002Date of Patent: May 20, 2003Assignee: Tsar Health Private Ltd.Inventor: Ranjit Kumar Chandra
-
Publication number: 20030092688Abstract: A water-dispersible and substantially non-combustible liquid vitamin composition comprising one or more of Vitamins A, D3 and E, or a precursor thereof, and an emulsifier, an alkyl lactate and water.Type: ApplicationFiled: August 3, 2001Publication date: May 15, 2003Inventor: Michel Andre Crepeau
-
Patent number: 6562378Abstract: A multinutrient nutritional supplement is provided that is designed to be most effective in optimizing health, increasing the immunity and decreasing the instances and severity of infection particularly among adolescents.Type: GrantFiled: August 16, 2002Date of Patent: May 13, 2003Assignee: TSAR Health Private Ltd.Inventor: Renjit Kumar Chandra
-
Patent number: 6559139Abstract: This invention relates to combination chemotherapy, particularly involving vitamin D or a derivative thereof. In one aspect, the invention provides a method of killing a cell by first administering to the cell vitamin D (or a derivative) and subsequently administering to the cell a cytotoxic agent. Where this strategy is applied to an intact tumor, the present invention provides a method of retarding the growth of the tumor by first administering vitamin D (or a derivative) to the tumor and subsequently administering the cytotoxic agent. A further aspect of the invention concerns a method of treating prostate cancer within a patient by co-administration of vitamin D (or a derivative) and a glucocorticoid to the patient. In yet a further aspect, the invention provides an improved method of treating a patient with vitamin-D involving the adjunctive administration of zoledronate.Type: GrantFiled: April 6, 2000Date of Patent: May 6, 2003Assignee: University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Candace S. Johnson, Donald L. Trump
-
Publication number: 20030078243Abstract: A water-dispersible vitamin composition containing Vitamins A, D3 or E, or a precursor thereof, an alkyl lactate and an emulsifier and is substantially free of water.Type: ApplicationFiled: August 3, 2001Publication date: April 24, 2003Inventor: Michel Andre Crepeau
-
Publication number: 20030077254Abstract: Various compositions containing transfer factor in combination with nutraceuticals are provided including transfer factor in combination with zinc and essential fatty acids and transfer factor in combination with lactic acid generating bacteria. Also provided are methods for treating animal diseases and syndromes using these compositions.Type: ApplicationFiled: April 30, 2002Publication date: April 24, 2003Inventor: Joseph C. Ramaekers
-
Patent number: 6552009Abstract: A composition is described comprising a vitamin D analog and a retinoid wherein: (a) the vitamin D analog is capable of binding a vitamin D receptor or being converted in vivo into a compound capable of binding a vitamin D receptor; and (b) the retinoid is selected from the group consisting of retinol in a concentration of at least about 1.0% and a retinoid characterized by having a substitution at the 4-position. Further, methods of treating disorders characterized by abnormal cell-proliferation and/or cell-differentiation are also described.Type: GrantFiled: June 1, 2001Date of Patent: April 22, 2003Assignee: Gentrix LLCInventor: Charles C. Achkar
-
Patent number: 6552074Abstract: A mixture obtained by mixing ascorbic acid powder with arginine powder in a weight ratio (ascorbic acid/arginine) of ⅕ to 20, especially ⅕ to ¼; and a supplement such as a nutrient preparation and a health-care food containing the mixture. Mixing of arginine powder and ascorbic acid powder in the weight ratios eliminates stringent taste specific to arginine and alleviates stringent feeling in the stomach (heartburn, nausea or vomiting) after oral intake thereof. The mixture prevents also peroxidative injuries of cells caused by an administration of a great amount of arginine alone. Further, mixing of arginine powder with ascorbic acid powder prevents browning of the mixture after long-term storage.Type: GrantFiled: November 13, 2001Date of Patent: April 22, 2003Inventors: Eiji Kimoto, Fukumi Morishige
-
Patent number: 6537982Abstract: The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the prostate, e.g., prostatic cancer and prostatic hyperplasia, which includes administering to a patient in need thereof an active vitamin D analogue. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.Type: GrantFiled: February 23, 1998Date of Patent: March 25, 2003Assignee: Bone Care International, Inc.Inventors: Charles W. Bishop, Joyce C. Knutson, Richard B. Mazess
-
Publication number: 20030054058Abstract: The present invention provides a Vitex agnus castus extract wherein the extract is obtained by extracting dried and pulverized fruits of the plant Vitex agnus castus with a 90-100% ethanol solvent, separating the extraction solution from the rest of the plant material, removing the solvent from the extraction solution and recovering the extract. The present invention also provides for a dietary supplement comprising a Vitex agnus castus extract having a linoleic acid content of at least ten weight percent by the composition and a calcium source and the use of the extract and dietary supplement to treat conditions particularly affecting women.Type: ApplicationFiled: May 8, 2002Publication date: March 20, 2003Inventors: David Gregory Corley, Qing Lu, Ding Ming, John P. Troup
-
Patent number: 6531582Abstract: The present invention relates to the novel compound 2-O-(9z,12z-octadecadienoyl)-3-O-[&agr;-D-galactopyranosyl-(1″-6′)-O-&agr;-D-galactopyranosyl]glycerol (Generic name: shinbarometin) having the chemical structure represented by the following formula: or its acetate having an excellent effect on arthritis, osteoporosis and ruptured disc, and to a pharmaceutical composition containing said compound as an effective component, in combination with a pharmaceutically acceptable auxiliary, diluent, isotonic agent, preservative, lubricant and solubilizing aid, which is formulated in the form of a pharmaceutically acceptable preparation and has a potent effect for osteoporosis, arthritis and ruptured disc.Type: GrantFiled: November 29, 2001Date of Patent: March 11, 2003Inventors: Joon Shik Shin, Sang Tae Kim, Yong Nam Han
-
Patent number: 6531157Abstract: The present invention relates to stable emulsions and dry powders of mixtures of fat-soluble vitamins, and to processes for their preparation and to their use.Type: GrantFiled: March 21, 2000Date of Patent: March 11, 2003Assignee: BASF AktiengesellschaftInventors: Wolfgang Hähnlein, Morten Mohr Hansen, Jes Elenius Olesen, Anne Grethe Tobiasen
-
Patent number: 6521608Abstract: Treatment of hyperporliferative disorders (including tumors and psoriasis) by pulse administration of a drug (such as Vitamin D or an analog) that increases blood or tissue levels of Vitamin D. The drug is administered at a sufficient dose to have an anti-proliferative effect, but the pulsed administration of the drug avoids the development of severe symptomatic or life-threatening hypercalcemia. In particular embodiments, avoidance of hypercalcemia (as measured by serum levels of calcium above normal range) is avoided altogether. In a particular example, the drug is calcitriol administered at an oral dose of about 0.5 mcg/kg once a week.Type: GrantFiled: September 21, 2000Date of Patent: February 18, 2003Assignee: Oregon Health & Science UniversityInventors: William D. Henner, Tomasz M. Beer
-
Publication number: 20030032617Abstract: Methods and pharmaceutical compositions for use in the treatment of a benign and/or a malignant proliferative pathologies are disclosed. The methods comprise administration of nicotinamide or its analogs and/or cADPR or its analogs, optionally in combination with a vitamin D3 analog or a Vitamin A analog.Type: ApplicationFiled: July 11, 2002Publication date: February 13, 2003Inventors: Avikam Harel, Olga Bloch
-
Publication number: 20030012826Abstract: The present invention relates to compositions without added iron and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, alpha lipoic acid, and lutein, wherein the composition is free of added iron.Type: ApplicationFiled: October 19, 2001Publication date: January 16, 2003Inventors: John A. Giordano, Charles Balzer
-
Patent number: 6506413Abstract: Various compositions containing transfer factor in combination with nutraceuticals are provided including transfer factor in combination with zinc and essential fatty acids and transfer factor in combination with lactic acid generating bacteria. Also provided are methods for treating animal diseases and syndromes using these compositions.Type: GrantFiled: April 30, 2001Date of Patent: January 14, 2003Inventor: Joseph C. Ramaekers
-
Patent number: 6503893Abstract: Methods for the utilization of hypocalcemic vitamin D analogs to inhibit the hyperproliferation of malignant or neoplastic cells without incidence of hypercalcemia.Type: GrantFiled: June 26, 2001Date of Patent: January 7, 2003Assignee: Bone Care International, Inc.Inventors: Charles W. Bishop, Richard B. Mazess